Lever 3 — remove the sensitising drive
Lever 3 — remove the sensitising drive. Lever 3 removes the upstream sensitising drive — nerve-growth-factor (NGF→TrkA) and CGRP signalling that turn up the gain of the pain pathway. For every L3 target, γ only places the gene in the map; the ligand→receptor→sensitisation mechanism is cited biology, never derived by the read, and is enforced as [O] by
This lever groups the targets whose promoter reads place them in the lever 3 — remove the sensitising drive. Each target keeps its own page with its read, grades, citation, and firewall; the lever direction is cited Layer-2 biology, the reads are [V], and all clinical magnitudes are [O].
What this lever does
Lever 3 removes the upstream sensitising drive — nerve-growth-factor (NGF→TrkA) and CGRP signalling that turn up the gain of the pain pathway. For every L3 target, γ only places the gene in the map; the ligand→receptor→sensitisation mechanism is cited biology, never derived by the read, and is enforced as [O] by a fail-closed L3-honesty gate.
Targets in this lever
Each row links to that target's own self-contained page (its read, grades, citation, and firewall).
| gene | channel / protein | γ | |hsp| | selectivity (cited) |
|---|---|---|---|---|
| CALCB | beta-CGRP (ligand) | γ 1.5169 | |hsp| 0.71909 | CGRP isoform (trigeminal/enteric) |
| NTRK1 | TrkA (NGF receptor) | γ 1.5036 | |hsp| 0.709654 | nociceptor + some CNS (CIPA on LOF) |
| CALCA | alpha-CGRP (ligand) | γ 1.4876 | |hsp| 0.698357 | trigeminovascular; de-risked axis (gepants + anti-CGRP mAbs approved) |
| NGF | NGF (nerve growth factor, ligand) | γ 1.4688 | |hsp| 0.68516 | peripheral sensitiser; anti-NGF efficacy in OA/LBP (rapidly-progressive-OA caveat) |
| RAMP1 | RAMP1 (receptor-activity-modifying protein 1) | γ 1.4249 | |hsp| 0.654673 | confers CGRP specificity on CLR |
| CALCRL | CALCRL (calcitonin-receptor-like receptor) | γ 1.2122 | |hsp| 0.5137 | with RAMP1 forms the CGRP receptor; erenumab/gepant target |